Abstract
Polygenic risk scores (PRS) aggregate variants at multiple genetic loci to calculate the likelihood of developing a specific disease. These scores are developed using databases of individuals who have undergone testing, most from European ancestry. This may reduce accuracy for patients of underrepresented ancestral backgrounds. Economic models assessing the value of PRS without exploring the accuracy when used in a diverse population may inaccurately estimate the value of testing, leading to inappropriate coverage, reimbursement, and clinical implementation decisions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
